RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR..

Trial Profile

RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR..

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2011

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Hydrochlorothiazide; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top